Immunotherapy, Tumor Microenvironment and Survival Signaling
The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapi...
Saved in:
| Sonstige: | |
|---|---|
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 electronic resource (376 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993545272504498 |
|---|---|
| ctrlnum |
(CKB)5690000000012034 (oapen)https://directory.doabooks.org/handle/20.500.12854/87472 (EXLCZ)995690000000012034 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Golubovskaya, Vita edt Immunotherapy, Tumor Microenvironment and Survival Signaling Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (376 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer. English Medicine bicssc Clinical & internal medicine bicssc Autophagy colorectal cancer immunotherapy tumor stroma tumor microenvironment immune checkpoint inhibitors chemotherapy tyrosine kinase inhibitors angiogenesis check point inhibitors programmed cell death protein 1 programmed cell death 1 ligand 1 cardiotoxicity lung metastasis CAR-T hypoxia tumor microenvironment CD19 BCMA cancer melanoma immune escape antigen loss chimeric antigen receptor electroporation lentivirus lentiviral transduction macrophages leukemia cells lytic peptides targeted therapy dendritic cells pathogenesis risk factors breast cancer resistance checkpoint targeted treatment personalized medicine pediatric solid tumors chimeric antigen receptors cancer vaccines oncolytic viral therapy immunomodulation DCLK1 tumor stem cells clonogenicity mitochondria mitochondrial transfer tunneling nanotubes triple-negative breast cancer immune checkpoint inhibitor combination therapy cancer nanomedicine tumor antigens cancer metabolism cancer immunotherapy nanoparticles immunotherapeutic agent immunomodulators tuft cells cancer stem cells immunotherapies myeloid-derived suppressor cells regulatory T cells crosstalk tumor immune evasion cell-cell contact β2 integrins CD18 CD11 CAR-T cells CD37 cell therapy tumor antigen lymphoma CAR macrophage CAR T cell solid tumors immunometabolism miRNA immunogenic cell death 3-0365-4419-4 3-0365-4420-8 Golubovskaya, Vita oth |
| language |
English |
| format |
eBook |
| author2 |
Golubovskaya, Vita |
| author_facet |
Golubovskaya, Vita |
| author2_variant |
v g vg |
| author2_role |
Sonstige |
| title |
Immunotherapy, Tumor Microenvironment and Survival Signaling |
| spellingShingle |
Immunotherapy, Tumor Microenvironment and Survival Signaling |
| title_full |
Immunotherapy, Tumor Microenvironment and Survival Signaling |
| title_fullStr |
Immunotherapy, Tumor Microenvironment and Survival Signaling |
| title_full_unstemmed |
Immunotherapy, Tumor Microenvironment and Survival Signaling |
| title_auth |
Immunotherapy, Tumor Microenvironment and Survival Signaling |
| title_new |
Immunotherapy, Tumor Microenvironment and Survival Signaling |
| title_sort |
immunotherapy, tumor microenvironment and survival signaling |
| publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
| publishDate |
2022 |
| physical |
1 electronic resource (376 p.) |
| isbn |
3-0365-4419-4 3-0365-4420-8 |
| illustrated |
Not Illustrated |
| work_keys_str_mv |
AT golubovskayavita immunotherapytumormicroenvironmentandsurvivalsignaling |
| status_str |
n |
| ids_txt_mv |
(CKB)5690000000012034 (oapen)https://directory.doabooks.org/handle/20.500.12854/87472 (EXLCZ)995690000000012034 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
Immunotherapy, Tumor Microenvironment and Survival Signaling |
| author2_original_writing_str_mv |
noLinkedField |
| _version_ |
1787548734757797888 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04687nam-a2201297z--4500</leader><controlfield tag="001">993545272504498</controlfield><controlfield tag="005">20231214133149.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202207s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5690000000012034</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/87472</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995690000000012034</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Golubovskaya, Vita</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunotherapy, Tumor Microenvironment and Survival Signaling</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (376 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical & internal medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Autophagy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor stroma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tyrosine kinase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">angiogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">check point inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">programmed cell death protein 1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">programmed cell death 1 ligand 1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cardiotoxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lung metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CAR-T</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hypoxia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD19</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BCMA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune escape</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antigen loss</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chimeric antigen receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">electroporation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lentivirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lentiviral transduction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">macrophages</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">leukemia cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lytic peptides</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dendritic cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pathogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">risk factors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">checkpoint</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pediatric solid tumors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chimeric antigen receptors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer vaccines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncolytic viral therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunomodulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DCLK1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor stem cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clonogenicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mitochondria</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mitochondrial transfer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tunneling nanotubes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">triple-negative breast cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">combination therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer nanomedicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor antigens</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapeutic agent</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunomodulators</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tuft cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer stem cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">myeloid-derived suppressor cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulatory T cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">crosstalk</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor immune evasion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell-cell contact</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">β2 integrins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD18</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD11</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CAR-T cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD37</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor antigen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lymphoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CAR macrophage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CAR T cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">solid tumors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunometabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">miRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunogenic cell death</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4419-4</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4420-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Golubovskaya, Vita</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:44:55 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-07-14 08:50:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337864370004498&Force_direct=true</subfield><subfield code="Z">5337864370004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337864370004498</subfield></datafield></record></collection> |